Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts - Milan 2023

From the Editor's Desk

Chair(s): James D. Chalmers, Arzu Yorgancioglu, Jeffrey Drazen

Session type: Journal session

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Klaus F. Rabe

EVENTS HOME

Replay
Slides

Previous presentation

Next presentation

Session content

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

Klaus F. Rabe

Replay

Slides

Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomized, placebo-controlled, double-blind, investigator-initiated trial

Daiana Stolz

Replay

Slides

Hydrocortisone in Severe Community-Acquired Pneumonia

Pierre Francois Dequin

Replay

Slides

Effects of Sotatercept on Haemodynamics and Right Heart Function: Analysis of STELLAR Trial

Marius M. Hoeper

Replay

Slides

Discussion and Q&A

Replay

Session aims

The Editors of the ERJ and NEJM will introduce seminal papers that were published in the respective journal in 2023 which will then be presented by one of the authors.

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}